Cardiovascular risk factors in HIV-infected patients.
Highly active antiretroviral therapy (HAART) commonly leads to persistent dyslipidemia and insulin resistance that appear likely to confer an increased incidence of cardiovascular disease (CVD). Both protease inhibitors (PIs) and, to a lesser extent, nucleoside analog reverse transcriptase inhibitors (NRTIs) appear to be involved, through direct metabolic effects of PIs and an indirect effect of PI and NRTI-related lipodystrophy. Several studies have found a variable relationship between CVD incidence and HAART, but these studies were not prospective and may not have been adequately powered. A variety of treatment strategies have been evaluated for dyslipidemia and insulin resistance, including lifestyle changes, drugs, and antiretroviral switching, but their relative safety, efficacy and roles are unclear. Although treatment of dyslipidemia and insulin resistance is commonly recommended, it should be remembered that such therapy is likely to be of greater benefit in those with a greater perceived CVD risk (i.e., multiple risk factors) and the lowest risk of HIV disease progression.
Carr
Andrew
A
HIV Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, 2010, Australia. acarr@stvincents.com.au
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D002318:Cardiovascular Diseases / Q000150:complications*; D048909:Diabetes Complications; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D007333:Insulin Resistance; D012307:Risk Factors